Please login to the form below

Not currently logged in
Email:
Password:

Ablynx reshuffles its board again

Dr Bo Jesper Hansen resigns from the Belgium biotech's board

Dr Bo Jesper HansenAfter one month as Ablynx’s chairman of the board of directors, Dr Bo Jesper Hansen (pictured) has resigned from the position due to personal reasons.

Dr Hansen will be succeeded by Dr Russell Greig, who will also become a permanent representative of Greig Biotechnology Global Consulting.

Dr Greig has been non-executive director of Ablynx since 2012, and has been unanimously elected by the board to be the biotech’s new chairman.

To date he has served in various roles during his 28-year career at GlaxoSmithKline, where he most recently served as president for both GSK Pharmaceuticals and SROne, the venture arm of GSK.

Dr Edwin Moses, chief executive officer of Ablynx, said: “We are very fortunate to have a very suitable successor for Bo Jesper, allowing for an orderly transition at this time.

“Russell knows the company extremely well and will be an important asset during the next months.”

14th February 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

We're award-winning joint working specialists. We help our clients to transform healthcare through effective collaboration, and deliver work to feel...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics